Abstract:Background: Preterm labour is a major health challenge in obstetrics. Many risk factors being identified, the most common one is short cervical length, can be diagnosed by transvaginal ultrasound scan after 13 weeks of pregnancy. Vaginal progesterone is the most bioavailable form of progesterone that have effect on uterine and cervix. Progesterone is found to inhibit the production of proinflammatory cytokines and prostaglandins within the uterus and to inhibit myometrial contractility Aim:To evaluate the efficacy of vaginal progesterone administration for preventing preterm birth and decrease perinatal morbidity and mortality in asymptomatic women with a singleton gestation and a mid-trimester sonographic cervical length (CL)â€‰â‰¤â€‰25â€‰mm. Materials And Methods:This is a prospective study of asymptomatic women with a singleton pregnancy and a sonographic short cervix (<25mm) at 19 + 0 to 23 + 6 weeks of gestation. Women were allocated randomly to receive vaginal progesterone or placebo daily starting from 19 + 0 to 23 + 6 weeks until 36 + 6 weeks, rupture of membranes or delivery, whichever occurred first. Randomization sequence was stratified by centre and history of a previous preterm birth. The primary endpoint was preterm birth before 33 weeks of gestation. Analysis was by intention to treat. Results:Out of 100 patients for whom study was done, 20 lost to followup and remaining divided into two groups: 40 Singleton pregnant women with CL<25mm between 19 + 0 to 23 + 6 weeks of gestation with no sign and symptoms were given daily vaginal progesterone for up to 36 + 6 weeks, rupture of membranes or delivery, whichever occurred first. The dose is 200 mg once daily and a group of 40 women with cervical length of <25 mm between 19 + 0 to 23 + 6 weeks of pregnancy were given no treatment, Maximum distribution belongs to age of 19-24 years followed by 30-34 years. Most of women in this study have no history of preterm labour. In those who received vaginal progesterone 5 women had history of previous preterm labour and five women in no treatment group. It was found that there was statistically significant reduction in preterm labour in women with short cervix <2.5cm with 200mg vaginal progesterone. Conclusions:This updated systematic review and meta-analysis reaffirms that vaginal progesterone reduces the risk of preterm birth and neonatal morbidity and mortality in women with a singleton gestation and a mid-trimester CL â‰¤ 25 mm, without any deleterious effects on neurodevelopmental outcome. Clinicians should continue to perform universal transvaginal CL screening at 19 + 0 to 23 + 6 weeks of gestation in women with a singleton gestation and to offer vaginal progesterone to those with a CL â‰¤ 25 mm.

Principle and Control of Modified Cascaded NPC-GCI With Variable Topology Ability to Enhance European Efficiency

VAGINAL PROGESTERONE IN RISK REDUCTION OF PRETERM BIRTH IN WOMEN WITH SHORT CERVIX IN MID TRIMESTER OF PREGNANCY

Vaginal progesterone decreases preterm birth ≤ 34 weeks of gestation in women with a singleton pregnancy and a short cervix: an updated meta-analysis including data from the OPPTIMUM study

Nowgen, A Center for Genetics in Healthcare.

Topical antimicrobial therapy of chronic wounds healing by secondary intention using iodine products

Longitudinal Change in Cervical Length Measured after Prophylactic Cerclage in Predicting Spontaneous Preterm Birth.

Cerclage versus vaginal progesterone in low-risk pregnant women with a short cervix

Vaginal progesterone is as effective as cervical cerclage to prevent preterm birth in women with a singleton gestation, previous spontaneous preterm birth, and a short cervix: updated indirect comparison meta-analysis

The clinical utility of ongoing sonographic cervix length surveillance in pregnancies prescribed vaginal progesterone therapy

Vaginal Progesterone to Prevent Spontaneous Preterm Birth in Women With a Sonographic Short Cervix: The Story of the PREGNANT Trial

The effectiveness of vaginal progesterone in reducing preterm birth in high-risk patients diagnosed with short cervical length after 24 weeks: A retrospective cohort study

Pregnancy-related complications and perinatal outcomes following progesterone supplementation before 20 weeks of pregnancy in spontaneously achieved singleton pregnancies: a systematic review and meta-analysis

The effectiveness of vaginal progesterone to prevent preterm birth in singleton pregnant women with a short cervix at 18–32 weeks gestation

Implementation of universal screening for preterm delivery by mid-trimester cervical-length measurement

Effects of vaginal progesterone and placebo on preterm birth and antenatal outcomes in women with singleton pregnancies and short cervix on ultrasound: a meta-analysis

A new screening of preterm birth in gestation with short cervix after pessary plus progesterone

SMFM Consult Series #70: Management of short cervix in individuals without a history of spontaneous preterm birth

The myosin dimer: an intermediate in the self‐assembly of the thick filament of vertebrate skeletal muscle

Large Electroencephalographic Responses and Their Relationship to Cleido-Cranial Dysplasia

Contrast and Comparison of Behavioral, Cognitive-Behavioral, and Comprehensive Treatment Methods for Anorexia Nervosa and Bulimia Nervosa

Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety